Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.67 |
| ▸ | PARP14 | Q460N5 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903593 | 0.83 | MAPT (0.85) | PARP10PARP14MAPTCRHBPHTT | |
| SCHEMBL257897 | 0.80 | MEN1 (0.64) | PARP10PARP14MAPTCRHBPHTT | |
| SCHEMBL24489414 | 0.76 | MAPT (0.66) | PARP10PARP14MAPTCRHBPHTT | |
| SCHEMBL25910311 | 0.76 | MAOB (0.63) | PARP10PARP14MAPTCRHBPHTT | |
| SCHEMBL8736479 | 0.76 | MAOB (0.63) | PARP10PARP14MAPTCRHBPHTT | |
| SCHEMBL25910322 | 0.75 | MAPT (0.56) | PARP10PARP14MAPTCRHBPHTT | |
| SCHEMBL13257656 | 0.75 | ALDH1A1 (0.76) | PARP10PARP14MGLLHSD11B1 | |
| SCHEMBL25910319 | 0.74 | MAOB (0.57) | PARP10PARP14MAPTCRHBPHTT | |
| SCHEMBL564525 | 0.73 | RAB9A (0.70) | PARP10PARP14MAPTCRHBPHTT | |
| SCHEMBL4733674 | 0.72 | ALDH1A1 (0.52) | MAPTMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | PARP10 1667/4885PARP14 2378/4885MAPT 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.